BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33728909)

  • 1. Binimetinib Is a Potent Reversible and Time-Dependent Inhibitor of Cytochrome P450 1A2.
    Dong J; Li S; Liu G
    Chem Res Toxicol; 2021 Apr; 34(4):1169-1174. PubMed ID: 33728909
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Zhang N; Liu J; Chen Z; Dou W
    Pharm Biol; 2019 Dec; 57(1):571-576. PubMed ID: 31456483
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes.
    Masubuchi Y; Horie T
    Chem Res Toxicol; 1999 Oct; 12(10):1028-32. PubMed ID: 10525281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis.
    Atkinson A; Kenny JR; Grime K
    Drug Metab Dispos; 2005 Nov; 33(11):1637-47. PubMed ID: 16049126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibitory effects of suberosin on CYP1A2 in human liver microsomes.
    Paudel S; Jo H; Lee T; Lee S
    Biopharm Drug Dispos; 2023 Oct; 44(5):365-371. PubMed ID: 37448189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.
    Lu P; Schrag ML; Slaughter DE; Raab CE; Shou M; Rodrigues AD
    Drug Metab Dispos; 2003 Nov; 31(11):1352-60. PubMed ID: 14570767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro inhibitory effects of pristimerin on human liver cytochrome P450 enzymes.
    Hao X; Yuan J; Xu Y; Wang Z; Hou J; Hu T
    Xenobiotica; 2018 Dec; 48(12):1185-1191. PubMed ID: 28385095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver.
    Yang TJ; Sai Y; Krausz KW; Gonzalez FJ; Gelboin HV
    Pharmacogenetics; 1998 Oct; 8(5):375-82. PubMed ID: 9825829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by anti-tumor triazoloacridinone C-1305.
    Potęga A; Fedejko-Kap B; Mazerska Z
    Xenobiotica; 2016 Dec; 46(12):1056-1065. PubMed ID: 26928326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib.
    Amaya GM; Durandis R; Bourgeois DS; Perkins JA; Abouda AA; Wines KJ; Mohamud M; Starks SA; Daniels RN; Jackson KD
    Chem Res Toxicol; 2018 Jul; 31(7):570-584. PubMed ID: 29847931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions.
    Karjalainen MJ; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2006 Dec; 34(12):2091-6. PubMed ID: 16985100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human liver microsomes study on the inhibitory effect of plantainoside D on the activity of cytochrome P450 activity.
    Zhou J; Qian X; Zhou Y; Xiong S; Ji S; Wang Y; Zhao P
    BMC Complement Med Ther; 2022 Jul; 22(1):197. PubMed ID: 35870998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a method to determine cytochrome P450 1A2, 2C9, 2D6 and 3A4 activity sheep hepatic microsomes.
    McBride GM; Soo JY; Varcoe T; Morrison JL; Wiese MD
    J Pharmacol Toxicol Methods; 2020; 106():106934. PubMed ID: 33080390
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Zhao H; Xue S; Meng Q; Zhou C
    Xenobiotica; 2021 Sep; 51(9):977-982. PubMed ID: 34176447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes.
    Potęga A; Fedejko-Kap B; Mazerska Z
    Pharmacol Rep; 2016 Aug; 68(4):663-70. PubMed ID: 27110874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes.
    Foroozesh M; Primrose G; Guo Z; Bell LC; Alworth WL; Guengerich FP
    Chem Res Toxicol; 1997 Jan; 10(1):91-102. PubMed ID: 9074808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human cytochrome p450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1'-hydroxymethyleugenol.
    Jeurissen SM; Bogaards JJ; Boersma MG; ter Horst JP; Awad HM; Fiamegos YC; van Beek TA; Alink GM; Sudhölter EJ; Cnubben NH; Rietjens IM
    Chem Res Toxicol; 2006 Jan; 19(1):111-6. PubMed ID: 16411663
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Li J; Wen H; Gao Z
    Xenobiotica; 2020 Feb; 50(2):231-236. PubMed ID: 31020909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes.
    Qi XY; Liang SC; Ge GB; Liu Y; Dong PP; Zhang JW; Wang AX; Hou J; Zhu LL; Yang L; Tu CX
    Food Chem Toxicol; 2013 Jun; 56():392-7. PubMed ID: 23500771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Inhibition of Human CYP450s 1A2, 2C9, 3A4/5, 2D6 and 2E1 by Grandisin.
    Habenschus MD; Moreira FL; Lopes NP; de Oliveira ARM
    Planta Med; 2017 May; 83(8):727-736. PubMed ID: 28073119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.